

106TH CONGRESS  
2D SESSION

# S. 2963

To amend title XIX of the Social Security Act to require the Secretary of Health and Human Services to make publicly available medicaid drug pricing information.

---

## IN THE SENATE OF THE UNITED STATES

JULY 27, 2000

Mr. BRYAN (for himself Mr. GRAHAM, and Mr. GORTON) introduced the following bill; which was read twice and referred to the Committee on Finance

---

## A BILL

To amend title XIX of the Social Security Act to require the Secretary of Health and Human Services to make publicly available medicaid drug pricing information.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Consumer Awareness  
5 of Market-Based Drug Prices Act of 2000”.

1 **SEC. 2. PUBLIC DISCLOSURE OF MARKET-BASED DRUG**  
2 **PRICING INFORMATION.**

3 (a) IN GENERAL.—Section 1927(b)(3)(D) of the So-  
4 cial Security Act (42 U.S.C. 1396r–8(b)(3)(D)) is amend-  
5 ed to read as follows:

6 “(D) PUBLIC AVAILABILITY OF INFORMA-  
7 TION.—

8 “(i) TIMELY AVAILABILITY OF INFOR-  
9 MATION.—Notwithstanding any other pro-  
10 vision of law, with respect to a manufac-  
11 turer with an agreement in effect under  
12 this section, not later than 30 days after  
13 the date the Secretary receives from such  
14 manufacturer the information required to  
15 be reported under this paragraph (or  
16 verifies such information with a whole-  
17 saler), the Secretary shall make the infor-  
18 mation described in clause (ii), including  
19 the identity of the manufacturer to which  
20 the information applies, publicly available  
21 through the Internet or other means of  
22 communication.

23 “(ii) INFORMATION DESCRIBED.—The  
24 information described in this clause is the  
25 following:

1           “(I) AVERAGE MANUFACTURER’S  
2 PRICE.—The average manufacturer  
3 price (as defined in subsection (k)(1))  
4 for each of the manufacturer’s covered  
5 outpatient drugs.

6           “(II) BEST PRICE.—With respect  
7 to single source drugs and innovator  
8 multiple source drugs, the manufac-  
9 turer’s best price (as defined in sub-  
10 section (c)(1)(C)) for each of the  
11 manufacturer’s covered outpatient  
12 drugs.

13           “(III) BASE AVERAGE MANUFAC-  
14 Turer PRICE AND INITIAL AVERAGE  
15 MANUFACTURER PRICE FOR NEWLY  
16 MARKETED DRUGS USED TO DETER-  
17 MINE AN ADDITIONAL REBATE FOR  
18 SINGLE SOURCE AND INNOVATOR  
19 MULTIPLE SOURCE DRUGS.—The av-  
20 erage manufacturer price described in  
21 subparagraphs (A)(ii)(II) (without re-  
22 gard to the percentage increase deter-  
23 mined under that subparagraph) and  
24 (B) of subsection (c)(2) for each dos-  
25 age form and strength of a single

1 source drug or an innovator multiple  
2 source drug used to determine, with  
3 respect to a rebate period, an addi-  
4 tional rebate for such dosage form  
5 and strength for such a drug.

6 “(iii) NONDISCLOSURE OF CERTAIN  
7 INFORMATION.—Notwithstanding any  
8 other provision of law, information dis-  
9 closed by manufacturers (or verified with  
10 wholesalers) under an agreement with the  
11 Secretary of Veterans Affairs described in  
12 subsection (a)(6)(A) may not be disclosed  
13 except—

14 “(I) as the Secretary determines  
15 to be necessary to carry out this sec-  
16 tion;

17 “(II) to permit the Comptroller  
18 General to review the information pro-  
19 vided; or

20 “(III) to permit the Director of  
21 the Congressional Budget Office to re-  
22 view the information provided.

23 “(iv) RULE OF CONSTRUCTION.—  
24 Nothing in this subparagraph shall be con-  
25 strued as affecting any requirement appli-

1 cable to the Secretary of Veterans Affairs  
2 regarding the confidentiality of information  
3 required to be disclosed to the Secretary of  
4 Veterans Affairs by a manufacturer under  
5 section 8126 of title 38, United States  
6 Code.”.

7 (b) EFFECTIVE DATE; IMPLEMENTATION.—

8 (1) EFFECTIVE DATE.—The amendments made  
9 by subsection (a) take effect upon the date of enact-  
10 ment of this Act and apply to the most recent re-  
11 ported price information under section 1927(b)(3) of  
12 the Social Security Act (42 U.S.C. 1396r–8(b)(3))  
13 as of such date, and all such information reported  
14 under such section after such date.

15 (2) ADDITIONAL PERIOD FOR IMPLEMENTA-  
16 TION.—Notwithstanding the 30-day requirement for  
17 the public availability of market-based drug pricing  
18 information under section 1927(b)(3)(D)(i) of the  
19 Social Security Act (42 U.S.C. 1396r–  
20 8(b)(3)(D)(i)), with respect to the initial public  
21 availability of such information, the Secretary of  
22 Health and Human Services shall have up to 90  
23 days from the date of the enactment of this Act in  
24 which to make such information so available.

1 **SEC. 3. AUTHORIZATION OF APPROPRIATIONS.**

2       There are authorized to be appropriated to carry out  
3 section 1927(b)(3)(D) of the Social Security Act (42  
4 U.S.C. 1396r-8(b)(3)(D)), as amended by section 2(a),  
5 such sums as may be necessary to carry out such section.  
6 Amounts appropriated pursuant to this section shall be  
7 in addition to amounts otherwise appropriated to carry out  
8 title XIX of such Act (42 U.S.C. 1396 et seq.).

○